Track topics on Twitter Track topics that are important to you
Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...
The faulty INRatio device used in the rivaroxaban ROCKET atrial fibrillation trial1 is particularly important in light of another drawback to this novel oral anticoagulant (NOAC). Rivaroxaban has the....
This retrospective study suggests that anti-inflammatory therapies, such as colchicine, are associated with lower CV risk.
A large Phase IV registry study shows that rivaroxaban is associated with a very low incidence of major bleeding, death, or stroke. Also, adherence to therapy was much higher than observed in other st...
An evidence review of 39 clinical trials found that patients who received continuous long-term treatment with colchicine had no reduction in all-cause mortality or cardiovascular mortality.
* Fda's regulatory approval of hikma's colchicine 0.6 mg capsule product was upheld.
In elderly patients with nonvalvular atrial fibrillation (AF), dabigatran and rivaroxaban provide comparable protection against thromboembolic stroke but dabigatran is safer, according to a new analys...
Rivaroxaban could be a safe treatment option for antiphospholipid syndrome, an important finding for people with lupus, says research published in The Lancet Haematology. Thrombotic antiphospholipid s...
This Clinical Evidence Synopsis summarizes a Cochrane review of clinical trials comparing the effects of long-term colchicine treatment with usual care or placebo on cardiovascular events in patients ...
Colchicine has been suggested to be beneficial in preventing recurrent pericarditis. The goal of this study was to review all randomized controlled trials that assess the use of colchicine for the pre...
Colchicine is an anti-inflammatory drug that is used for a wide range of inflammatory diseases. Cardiovascular disease also has an inflammatory component but the effects of colchicine on cardiovascula...
The aims of this study were to investigate the effects of rivaroxaban on routine coagulation assays using our local, widely available, reagents and to study the relationship between sensitive coagulat...
Is continuous long-term treatment with colchicine associated with lower rates of all-cause mortality and myocardial infarction and higher rates of adverse events?
Activated protein C resistance (APC-R) is assessed as part of thrombophilia screening, preferably in patients not taking oral anticoagulants. Rivaroxaban is known to alter some APC-R assays. To our kn...